Panavir is antiviral drug for external use, has viralstatic action. Active against Herpes simplex virus types I and II. Panavir ® inhibits the replication of viruses and polymerase reactions by blocking viral DNA synthesis in infected cells of the skin .
Indications for use:
Infectious and inflammatory diseases of the skin caused by the herpes simplex virus Herpes simplex types I and II (including genital herpes).
Externally. The gel is applied thinly to the affected areas of the skin and / or mucous 5 times a day . Duration of treatment is 4-5 days. The course of treatment may be extended to 10 days. Vaginally . Small amount of gel administered vaginally and spread it evenly with a thin layer on the walls of the vagina. Treatment is continued until the complete disappearance of clinical manifestations.
Hypersensitivity to the drug, pregnancy, lactation.
May occur quickly passing redness and itching at the application site skin gel.
Pregnancy and lactation Safety of Panavir during pregnancy and lactation has not been studied , so it should not be used during pregnancy and breastfeeding , except when medically potential benefit to the mother outweighs the potential risk to the fetus. In experimental animal studies, adverse effects on reproduction and fetal development has been established. It is recommended to start treatment at an early stage of the disease is possible , at the first signs (itching , tingling , redness, feeling of tension ) , in this case the development of the bubble stage of the disease can be completely prevented. Panavir ® gel should not be used in ophthalmology. When the gel is applied to the face to avoid it falling into his eyes.
In a dry, dark place at a temperature of 4 to 25 ° C , out of reach of children.